
FDA Approves Microbiome Therapeutic Vowst to Prevent Recurrence of C. difficile Infections in Adults
Seres Therapeutics and Nestlé Health Science celebrate the FDA's approval of Vowst, a first-of-its-kind orally administered microbiota-based therapeutic set to transform the lives of patients with recurrent C. difficile infections.
































